Hepatocellular Carcinoma in the Pediatric Population: A Population Based Clinical Outcomes Study Involving 257 Patients from the Surveillance, Epidemiology, and End Result (SEER) Database (1973–2011)
Table 4
Demographic profiles of fibrolamellar and nonfibrolamellar hepatocellular carcinoma for 63,514 adults and 257 pediatric patients from the Surveillance, Epidemiology, and End Results (SEER) database, 1973–2011.
Total
Pediatrics
Adults
value
fHCC
Non-fHCC
fHCC
Non-fHCC
fHCC
Non-fHCC
(%)
274 (0.4%)
63,497 (99.6%)
62 (24.1%)
195 (75.9%)
212 (0.3%)
63,302 (99.7%)
—
Age, (mean ± SD)
64 ± 12
63 ± 12
14 ± 4
13 ± 4
64 ± 12
63 ± 12
—
Gender, (%)
Male
164 (59.9%)
47,698 (75.1%)
34 (54.8%)
119 (61.0%)
130 (61.3%)
47,579 (75.2%)
<0.001
Female
110 (40.1%)
15,799 (24.9%)
28 (45.2%)
76 (39.0%)
82 (38.7%)
15,723 (24.8%)
<0.001
Race, (%)
Caucasian
175 (64.1%)
31,955 (50.5%)
35 (56.5%)
93 (48.4%)
140 (66.4%)
31,862 (50.5%)
NS
African American
32 (11.7%)
7,797 (12.3%)
9 (14.5%)
20 (10.4%)
23 (10.9%)
7,777 (12.3%)
NS
Hispanic
40 (14.7%)
10,245 (16.2%)
15 (24.2%)
34 (17.7%)
25 (11.8%)
10,211 (16.2%)
NS
Asian/Pacific Islander/Native Americans
26 (9.5%)
13,321 (21.0%)
3 (4.8%)
45 (23.4%)
23 (10.9%)
13,276 (21.0%)
NS
fHCC = fibrolamellar hepatocellular carcinoma; = number; NS = not statistically significant with value > 0.05; SD = standard deviation; data presented for patients with available information only.
